Actively Recruiting

Phase Not Applicable
Age: 18Years - 79Years
All Genders
NCT06653387

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

Led by InspireMD · Updated on 2025-05-31

50

Participants Needed

8

Research Sites

156 weeks

Total Duration

On this page

Sponsors

I

InspireMD

Lead Sponsor

W

Washington University School of Medicine

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures in the treatment of carotid artery stenosis in spatients at high risk for adverse events from carotid endarterectomy.

CONDITIONS

Official Title

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

Who Can Participate

Age: 18Years - 79Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is 18 years or older and younger than 80 years of age.
  • Willing and able to provide informed consent, follow protocol procedures, and attend follow-up visits.
  • Diagnosed with carotid artery disease suitable for carotid artery stenting via the Transcarotid Artery Revascularization approach.
  • Either symptomatic carotid stenosis 50% or greater with symptoms (amaurosis fugax, transient ischemic attack, or stroke within last 6 months) or asymptomatic carotid stenosis 80% or greater.
  • High risk for carotid endarterectomy with at least one of the following comorbidities or anatomic conditions: age 70 or older, severe angina, congestive heart failure class III-IV, low left ventricular ejection fraction (35% or less), recent myocardial infarction (3 days to 6 weeks before procedure), multi-vessel coronary artery disease with angina, severe COPD with low lung function, permanent contralateral cranial nerve injury, restenosis after previous carotid endarterectomy, planned coronary artery bypass or valve surgery in 31-60 days after stenting, planned abdominal aortic aneurysm repair in 31-60 days after stenting, occlusion of contralateral carotid arteries, prior neck radiation or surgery, severe bilateral internal carotid artery stenosis, target lesion at or above jaw level or below clavicle, severe tandem lesions, inability to extend neck, laryngeal palsy or laryngectomy, tracheostomy, spinal immobility of the neck, hostile neck or surgically inaccessible lesion.
  • Target lesion location at carotid bifurcation or proximal internal carotid artery.
  • Stent landing zone diameter between 4.8 mm and 9.0 mm.
  • Target lesion length 36 mm or less that can be covered by a single stent.
  • At least 5 cm disease-free common carotid artery segment suitable for access, sheath insertion, and clamping.
Not Eligible

You will not qualify if you...

  • Interventional procedure or surgery on carotid, coronary, or peripheral arteries within 30 days before or after the carotid procedure.
  • Open heart surgery, valvular intervention, or major operation within 30 days before or after the carotid procedure.
  • Vascular anatomy preventing safe sheath insertion or stent delivery.
  • Previously placed stent in the ipsilateral internal or common carotid artery.
  • Total occlusion or "string sign" of the ipsilateral carotid artery.
  • Presence of a filling defect or tandem lesions not coverable by a single stent.
  • Stenosis of the innominate artery or proximal common carotid artery needing revascularization.
  • Open neck stoma.
  • History of bleeding disorders or coagulopathy.
  • Hypercoagulable state.
  • Alternative sources of cerebral embolus such as chronic or recent atrial fibrillation, certain cardiac abnormalities, recent heart valve implantation, or abnormal angiographic findings.
  • Known allergy to nickel or titanium.
  • Sensitivity to contrast media not manageable by pre-treatment.
  • Sensitivity to both heparin and bivalirudin anticoagulation strategies.
  • Sensitivity to antiplatelet agents and all alternative antiplatelet options.
  • Known intolerance to statins.
  • Life expectancy less than 3 years.
  • Malignancy without specialist assessment of life expectancy.
  • Evolving stroke, recent intracranial hemorrhage, or brain surgery within past 12 months.
  • Stroke within 7 days that increases hemorrhage risk.
  • History of major stroke with significant neurologic deficit.
  • Recent transient ischemic attack, amaurosis fugax, or stroke within 48 hours.
  • Female who is pregnant, lactating, or planning pregnancy.
  • Dementia or neurologic condition interfering with assessments.
  • Conditions making endovascular therapy impossible or unsafe.
  • Prior enrollment in this trial.
  • Likely non-compliance with follow-up or medication.
  • Participation in another clinical trial that may interfere with this study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

UC Davis Health

Sacramento, California, United States, 95817

Actively Recruiting

2

Indiana University School of Medicine

Indianapolis, Indiana, United States, 46202

Actively Recruiting

3

Allina

Minneapolis, Minnesota, United States, 55407

Actively Recruiting

4

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

5

Benefis Health System

Great Falls, Montana, United States, 59405

Actively Recruiting

6

Mount Sinai Hospital

New York, New York, United States, 10029

Actively Recruiting

7

University of Rochester

Rochester, New York, United States, 14642

Actively Recruiting

8

TriHealth

Cincinnati, Ohio, United States, 45220

Actively Recruiting

Loading map...

Research Team

I

InspireMD/NAMSA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here